“There is a growing list of approved targets and therapies included in the 2018 NCCN Guidelines for Non–Small Cell Lung Cancer [NSCLC] as well as emerging targets. Why does this matter? Because targeted therapies improve survival,” said Karen L. Reckamp, MD, MS, Co-Director, Lung Cancer and Thoracic Oncology Program, and Professor, City of Hope Comprehensive Cancer Center.
“With no targeted therapy, median survival for a select group of patients with NSCLC is 2 years. If there is an oncologic driver and no targeted therapy is given, median overall survival [OS] is approximately 2 years. But, when there is an oncologic driver and targeted therapy is given, median OS jumps to over 3 years,” she told the audience at the NCCN 23rd Annual Conference.1
The list of mutations with approved targeted therapies includes EGFR mutations (present in 30%–40% of Asians2 and 10%–20% of Caucasians),3 ALK rearrangements (present in up to 7%), ROS1 rearrangements (1.7%), and BRAF mutations (present in 2%). Other targets with therapies that are not approved for use in NSCLC include HER2 (present in 2%), RET (present in 1.7%), MET (present in 10%), and NTRK (present in <1%).
The 2018 NCCN Guidelines recommend molecular testing to make the initial diagnosis, and this is then followed by PD-L1 testing. For adenocarcinoma, testing is recommended for EGFR, ALK, ROS1, and BRAF mutations as part of broad molecular profiling, in addition to PD-L1 testing. For squamous cell carcinoma, the recommendation is to consider testing for the same 4 mutations in a subset of patients and to perform PD-L1 testing in all patients.
Dr. Reckamp has disclosed that she has received grant/research support from AbbVie; ACEA; Adaptimmune; ARIAD Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Genentech, Inc.; Guardant; Loxo Oncology; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Seattle Genetics; and Xcovery. She has also received consulting fees/honoraria from Amgen Inc., ARIAD Pharmaceuticals, Inc., Astellas, Euclises, and Tesaro, Inc.
Kris MG, Johnson BE, Berry LD et al.. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 2014;11:1998–2006.
Mok TS, Wu YL, Thongprasert S et al.. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
Rosell R, Moran T, Queralt C et al.. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–967.
Wu YL, Cheng Y, Zhou X et al.. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomized, open-label, phase 3 trial. Lancet Oncol 2017;11:1454–1466.
Soria JC, Ohe Y, Vansteenkiste J et al.. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–125.
Peters S, Camidge DR, Shaw AT et al.. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829–838.
Hida T, Nokihara H, Kondo M et al.. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390:29–39.
Drilon A, Laetsch TW, Kummar S et al.. Efficacy of lacotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.